Specialty Veterinary Pharmacy (SVPMEDS) offers Molnupiravir Oral Anhydrous Liquid compounded for cats pursuant to patient-specific prescriptions from licensed veterinarians.
Molnupiravir, also known as EIDD-2801, is an antiviral compound that has been investigated in veterinary medicine, including in research involving Feline Infectious Peritonitis (FIP). SVPMEDS provides an oral anhydrous liquid dosage form that can be prepared in individualized concentrations according to the prescribing veterinarian’s instructions.
Our pharmacy also compounds molnupiravir capsules, providing veterinarians with additional formulation options for their patients.
SVPMEDS prepares molnupiravir in an oral anhydrous liquid formulation according to the requirements of an individual veterinary prescription.
Features of this dosage form include:
Based on SVPMEDS prescription dispensing history, commonly prescribed molnupiravir oral anhydrous liquid concentrations include:
Additional concentrations may be available based on the prescribing veterinarian’s requirements and pharmacy formulation capabilities. Contact SVPMEDS to discuss a specific prescription.
Feline Infectious Peritonitis (FIP) is a serious disease associated with feline coronavirus infection. Diagnosis and management require veterinary evaluation, and treatment decisions depend on the individual cat’s clinical condition.
Veterinary research has examined several antiviral compounds in relation to FIP, including molnupiravir and GS-441524. These compounds differ in their pharmacology, clinical evidence, and safety considerations.
For general educational information about the disease, visit Feline Infectious Peritonitis at VeterinaryPartner (VIN).
External educational resources are provided for general information and do not constitute an endorsement or claim regarding the safety or effectiveness of SVPMEDS compounded preparations.
SVPMEDS prepares Molnupiravir Oral Anhydrous Liquid using established nonsterile compounding procedures and pharmacy quality-control practices.
Our pharmacists follow applicable compounding standards and pharmacy procedures addressing ingredient verification, formulation, preparation, labeling, and dispensing.
Each prescription is prepared according to the prescribing veterinarian’s instructions and the pharmacy’s applicable quality-control requirements.
Molnupiravir Oral Anhydrous Liquid should be administered only as directed by the prescribing veterinarian and according to the prescription label.
Important Handling Information: Individuals who are pregnant, may become pregnant, or are breastfeeding should consult the dispensing pharmacist and an appropriate healthcare professional about potential exposure and handling precautions.
SVPMEDS offers additional compounded antiviral formulations pursuant to patient-specific veterinary prescriptions.
SVPMEDS also compounds molnupiravir in capsule form. Contact our pharmacy team for information about available strengths and prescription requirements.
GS-441524 is a separate antiviral compound available from SVPMEDS in a compounded oral liquid formulation. Learn more about GS-441524 Flavored Oral Liquid for Cats.
SVPMEDS also compounds GS-441524 capsules according to patient-specific veterinary prescriptions. Learn more about GS-441524 Capsules for Cats.
Another available GS-441524 dosage form is a compounded flavored soft chewable. Learn more about GS-441524 Flavored Soft Chewables for Cats.
These products contain different active ingredients or use different dosage forms and should not be considered interchangeable without direction from the prescribing veterinarian.
SVPMEDS compounds Molnupiravir Oral Anhydrous Liquid according to patient-specific prescriptions from licensed veterinarians. Each preparation is compounded based on the prescribed concentration, quantity, and administration instructions.
Prescription Required: A valid prescription from a licensed veterinarian is required before this medication can be prepared and dispensed.
Compounded Medication: Molnupiravir Oral Anhydrous Liquid is a compounded preparation and is not an FDA-approved animal drug. Compounding and dispensing are subject to applicable federal and state requirements.
It is a nonsterile compounded oral liquid preparation containing molnupiravir, prepared according to a patient-specific prescription from a licensed veterinarian.
Molnupiravir and GS-441524 are different antiviral compounds. Both have been investigated in veterinary research involving FIP, but they differ in their pharmacology, safety considerations, and clinical evidence. The prescribing veterinarian determines which medication, if any, is appropriate for an individual patient.
SVPMEDS commonly compounds 50 mg/mL, 75 mg/mL, 100 mg/mL, and 200 mg/mL concentrations based on prescription history. Additional concentrations may be available upon review of the veterinarian’s prescription.
An oral liquid provides an alternative to capsule administration and allows the prescribed dose to be measured using an oral dosing syringe. The veterinarian determines whether this dosage form is appropriate for the individual patient.
Yes. SVPMEDS also compounds molnupiravir capsules according to patient-specific veterinary prescriptions.
Yes. Molnupiravir has potential reproductive and genetic toxicity concerns. Caregivers should follow the handling instructions supplied by the pharmacy and consult the pharmacist regarding potential exposure risks.
Follow the storage instructions and beyond-use date on the prescription label. Contact SVPMEDS if additional guidance is needed.
No. Compounded Molnupiravir Oral Anhydrous Liquid is not an FDA-approved animal drug.
Yes. A valid patient-specific prescription from a licensed veterinarian is required before SVPMEDS can prepare and dispense this medication.
Veterinarians and existing SVPMEDS customers can access the SVPMEDS Portal to submit patient-specific prescriptions and use available ordering services.
For questions about compounded molnupiravir concentrations, dosage forms, or prescription requirements, contact our pharmacy team.